Accelerating drug target inhibitor discovery with a deep generative foundation model
Inhibitor discovery for emerging drug-target proteins is challenging, especially when target structure or active molecules are unknown. Here, we experimentally validate the broad utility of a deep generative framework trained at-scale on protein sequences, small molecules, and their mutual interactions-unbiased toward any specific target. We performed a protein sequence-conditioned sampling on the generative foundation model to design small-molecule inhibitors for two dissimilar targets: the spike protein receptor-binding domain (RBD) and the main protease from SARS-CoV-2. Despite using only the target sequence information during the model inference, micromolar-level inhibition was observed in vitro for two candidates out of four synthesized for each target. The most potent spike RBD inhibitor exhibited activity against several variants in live virus neutralization assays. These results establish that a single, broadly deployable generative foundation model for accelerated inhibitor discovery is effective and efficient, even in the absence of target structure or binder information.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Science advances - 9(2023), 25 vom: 23. Juni, Seite eadg7865 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chenthamarakshan, Vijil [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.06.2023 Date Revised 06.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.adg7865 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358445566 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358445566 | ||
| 003 | DE-627 | ||
| 005 | 20231226074745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.adg7865 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358445566 | ||
| 035 | |a (NLM)37343087 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chenthamarakshan, Vijil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accelerating drug target inhibitor discovery with a deep generative foundation model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2023 | ||
| 500 | |a Date Revised 06.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Inhibitor discovery for emerging drug-target proteins is challenging, especially when target structure or active molecules are unknown. Here, we experimentally validate the broad utility of a deep generative framework trained at-scale on protein sequences, small molecules, and their mutual interactions-unbiased toward any specific target. We performed a protein sequence-conditioned sampling on the generative foundation model to design small-molecule inhibitors for two dissimilar targets: the spike protein receptor-binding domain (RBD) and the main protease from SARS-CoV-2. Despite using only the target sequence information during the model inference, micromolar-level inhibition was observed in vitro for two candidates out of four synthesized for each target. The most potent spike RBD inhibitor exhibited activity against several variants in live virus neutralization assays. These results establish that a single, broadly deployable generative foundation model for accelerated inhibitor discovery is effective and efficient, even in the absence of target structure or binder information | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Hoffman, Samuel C |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, C David |e verfasserin |4 aut | |
| 700 | 1 | |a Lukacik, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Strain-Damerell, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Fearon, Daren |e verfasserin |4 aut | |
| 700 | 1 | |a Malla, Tika R |e verfasserin |4 aut | |
| 700 | 1 | |a Tumber, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Schofield, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Duyvesteyn, Helen M E |e verfasserin |4 aut | |
| 700 | 1 | |a Dejnirattisai, Wanwisa |e verfasserin |4 aut | |
| 700 | 1 | |a Carrique, Loic |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, Thomas S |e verfasserin |4 aut | |
| 700 | 1 | |a Screaton, Gavin R |e verfasserin |4 aut | |
| 700 | 1 | |a Matviiuk, Tetiana |e verfasserin |4 aut | |
| 700 | 1 | |a Mojsilovic, Aleksandra |e verfasserin |4 aut | |
| 700 | 1 | |a Crain, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Martin A |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Payel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 9(2023), 25 vom: 23. Juni, Seite eadg7865 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:25 |g day:23 |g month:06 |g pages:eadg7865 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.adg7865 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 25 |b 23 |c 06 |h eadg7865 | ||